CAJ | 학술논문

目的探讨弥漫大B细胞淋巴瘤( DLBCL)患者化疗前后外周血T淋巴细胞亚群、NK细胞的变化与治疗效果的关系.方法收集经病理确诊且治疗有效的DLBCL患者47例,分别于化疗前及化疗第2个周期、第4个周期结束后第3天采集静脉血,经流式细胞术测定T淋巴细胞亚群及NK细胞,比较化疗前与化疗后T淋巴细胞亚群、NK细胞水平的差异,并与同期健康体检者50名进行比较.结果 DLBCL患者组化疗前外周血CD3+、CD4+、CD4+/CD8+、NK细胞表达水平[(70.04±8.87)％、(42.79±6.06)％、(1.68±0.59)％、(14.40±6.02)％]较健康对照组[(63.89±6.67)％、(32.72±5.77)％、( 0.85±0.25)％、(9.95±5.24)％]低(P＜0.05),而CD8+细胞表达水平较健康对照组高[(27.21±6.54)％比(39.92±7.11)％](P＜0.05).DLBCL患者组化疗第4个周期外周血CD3+、CD4+、CD4+/CD8+表达水平与化疗第2个周期相比差异均有统计学意义(均P＜ 0.05),该组患者化疗第4个周期CD3+、CD4+、CD8+、CD4+/CD8+、NK细胞表达水平与治疗前相比差异均有统计学意义(均P＜0.05).结论初治DLBCL患者体内存在着免疫抑制,外周血T淋巴细胞亚群及NK细胞可作为反映DLBCL患者机体细胞免疫功能的较好参数,在临床上可用于免疫功能的监测,为DLBCL治疗方案的选择提供指导意义.
목적 탐토미만대B세포림파류( DLBCL)환자화료전후외주혈T림파세포아군、NK세포적변화여치료효과적관계.방법 수집경병리학진차치료유효적DLBCL환자47례,분별우화료전급화료제2개주기、제4개주기결속후제3천채집정맥혈,경류식세포술측정T림파세포아군급NK세포,비교화료전여화료후T림파세포아군、NK세포수평적차이,병여동기건강체검자50명진행비교.결과 DLBCL환자조화료전외주혈CD3+、CD4+、CD4+/CD8+、NK세포표체수평[(70.04±8.87)％、(42.79±6.06)％、(1.68±0.59)％、(14.40±6.02)％]교건강대조조[(63.89±6.67)％、(32.72±5.77)％、( 0.85±0.25)％、(9.95±5.24)％]저(P＜0.05),이CD8+세포표체수평교건강대조조고[(27.21±6.54)％비(39.92±7.11)％](P＜0.05).DLBCL환자조화료제4개주기외주혈CD3+、CD4+、CD4+/CD8+표체수평여화료제2개주기상비차이균유통계학의의(균P＜ 0.05),해조환자화료제4개주기CD3+、CD4+、CD8+、CD4+/CD8+、NK세포표체수평여치료전상비차이균유통계학의의(균P＜0.05).결론 초치DLBCL환자체내존재착면역억제,외주혈T림파세포아군급NK세포가작위반영DLBCL환자궤체세포면역공능적교호삼수,재림상상가용우면역공능적감측,위DLBCL치료방안적선택제공지도의의.
Objective To investigate peripheral blood T lymphocyte subsets and NK cells changes in the diffuse large B cell lymphoma (DLBCL) patients before and after chemotherapy,and analyse the relationship between the results and treatment.Methods Collect the 47 patients venous blood of the effective treatment DLBCL by pathology.T lymphocyte subsets and NK cells were determined by flow cytometric.Analyse the results statistically significant difference before treatment,the second chemotherapy cycle and the fourth chenmotherapy cycle compared with 50 healthy control persons.Results The levels of CD3+,CD4+,CD4+/CD8+ NK cells in DLBCL patients before chemotherapy [(70.04±8.87)％,(42.79±6.06)％,(1.68±0.59)％,(14.40±6.02)％]were lower than healthy controls [(63.89±6.67)％,(32.72±5.77)％,(0.85±0.25)％,(9.95±5.24)％](P ＜ 0.05),and the level of CD8+ cells is higher than the healthy controls [(27.21 ±6.54)％ vs.(39.92±7.11)％](P ＜ 0.05).The levels of CD3+,CD4+,CD4+/CD8+ cells had significant difference between the second and the fourth chemotherapy cycle in DLBCL patients (P ＜ 0.05).The levels of CD3+,CD4+,CD8+,CD4+/CD8+,NK cells had significant difference between the fourth chemotherapy cycle DLBCL patients and the DLBCL patients before chemotherapy (P ＜ 0.05).Conclusion The DLBCL patients exist immunosuppression before chemotherapy.Peripheral T lymphocyte subsets and NK cells can be used as good reflect of the cellular immune function in DLBCL patients.Clinical parameters can be used for the immune function monitoring and providing guidance for the treatment options.